Phage-specific antibodies: are they a hurdle for the success of phage therapy?
Essays in Biochemistry · 17.12.2024 · 68 (5) · 633-644
DOI: 10.1042/ebc20240024 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Essays in Biochemistry, online erschienen am 17.12.2024. Verfasst von Ayaka Washizaki und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Phage Biologics, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu City, Gifu 501-1194, Japan. Hauptthemen laut MEDLINE: Phage Therapy, Bacteriophages. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Astellas Pharma (Astellas), Japan Society for the Promotion of Science (JSPS).
Abstract (Originalsprache)
Phage therapy has attracted attention again owing to the increasing number of drug-resistant bacteria. Although the efficacy of phage therapy has been reported, numerous studies have indicated that the generation of phage-specific antibodies resulting from phage administration might have an impact on clinical outcomes. Phage-specific antibodies promote phage uptake by macrophages and contribute to their rapid clearance from the body. In addition, phage-specific neutralizing antibodies bind to the phages and diminish their antibacterial activity. Thus, phage-specific antibody production and its role in phage therapy have been analyzed both in vitro and in vivo. Strategies for prolonging the blood circulation time of phages have also been investigated. However, despite these efforts, the results of clinical trials are still inconsistent, and a consensus on whether phage-specific antibodies influence clinical outcomes has not yet been reached. In this review, we summarize the phage-specific antibody production during phage therapy. In addition, we introduce recently performed clinical trials and discuss whether phage-specific antibodies affect clinical outcomes and what we can do to further improve phage therapy regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Phage Biologics, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu City, Gifu 501-1194, Japan.
- Center for One Medicine Innovative Translational Research (COMIT), Institute for Advanced Study, Gifu University, 1-1 Yanagido, Gifu City, Gifu 501-1194, Japan.
- Venture Unit Engineered Phage Therapy, Discovery Accelerator, Astellas Pharma Inc., Tsukuba City, Ibaraki 305-8585, Japan.
ORCID-Profile: Hiroki Ando
Förderung
- Astellas Pharma (Astellas)
- Japan Society for the Promotion of Science (JSPS)
Zitieren
APA
Washizaki, A., Sakiyama, A., & Ando, H. (2024). Phage-specific antibodies: are they a hurdle for the success of phage therapy?. Essays in Biochemistry, 68(5), 633-644. https://doi.org/10.1042/ebc20240024
Vancouver
Washizaki A, Sakiyama A, Ando H. Phage-specific antibodies: are they a hurdle for the success of phage therapy?. Essays in Biochemistry. 2024;68(5):633-644. doi:10.1042/ebc20240024
BibTeX
@article{Washizaki2024,
author = {Washizaki, Ayaka and Sakiyama, Arata and Ando, Hiroki},
title = {Phage-specific antibodies: are they a hurdle for the success of phage therapy?},
journal = {Essays in Biochemistry},
year = {2024},
volume = {68},
number = {5},
pages = {633--644},
doi = {10.1042/ebc20240024}
}
EUVIMED